Not recruiting

Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema

Fast replyInvestigational

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called Upadacitinib on individuals with moderate to severe Atopic Dermatitis, commonly known as eczema. Eczema is a condition that causes the skin to become itchy, red, and inflamed. The study involves both adolescents and adults who are candidates for systemic therapy, which means they may need treatment that affects the entire body rather than just the skin.

The purpose of the study is to evaluate the effectiveness and safety of Upadacitinib, which is a type of medication known as a Janus Kinase (Jak) 1 Inhibitor. This medication is taken orally in the form of a modified-release tablet, which means it is designed to release the active ingredient slowly over time. Participants in the study will receive either Upadacitinib or a placebo, which is a substance with no active medication, to compare the outcomes.

Throughout the study, participants will be monitored to see how their eczema symptoms change over time. The study will last for several months, and participants will have regular check-ups to assess their skin condition and overall health. The goal is to determine if Upadacitinib can significantly improve the symptoms of eczema and enhance the quality of life for those affected by this condition.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Initial visit
Upon joining the study, an initial visit is conducted to confirm eligibility. This involves a review of medical history and a physical examination.
Participants are informed about the study procedures, potential risks, and benefits. Consent is obtained before proceeding.
Step 2
Randomization
Participants are randomly assigned to receive either the study medication, upadacitinib, or a placebo. This process is double-blind, meaning neither the participant nor the study team knows which treatment is being administered.
Step 3
Medication administration
Participants take the assigned medication orally in the form of a modified-release tablet. The dosage and frequency are determined by the study protocol.
The duration of medication administration is up to 16 weeks, with regular monitoring throughout this period.
Step 4
Follow-up visits
Regular follow-up visits are scheduled to monitor the participant's health and response to the treatment. These visits include physical examinations and assessments of atopic dermatitis symptoms.
Participants are required to report any side effects or changes in their condition during these visits.
Step 5
Final assessment
At the end of the 16-week period, a final assessment is conducted to evaluate the effectiveness and safety of the treatment.
This includes a comprehensive review of the participant's health status and any changes in atopic dermatitis symptoms.

Who can join the trial?

3 criteria

Participants must be male or female and between 12 to 75 years old.
Participants must have active moderate to severe atopic dermatitis. This is a skin condition that can cause redness, swelling, and itching. It is measured by specific tools: EASI (Eczema Area and Severity Index), IGA (Investigator's Global Assessment), BSA (Body Surface Area), and pruritus (itchiness).
Participants must be candidates for systemic therapy or have recently needed systemic therapy for atopic dermatitis. Systemic therapy means treatment that affects the entire body, not just the skin.

Who cannot join the trial?

10 criteria

Patients with any other skin conditions that might interfere with the study results.
Patients who have had a serious infection in the past 12 weeks.
Patients who have been treated with certain medications that affect the immune system in the past 4 weeks.
Patients with a history of cancer, except for certain types of skin cancer that have been treated.
Patients who are pregnant or breastfeeding.
Patients with a history of severe allergic reactions to the study medication or similar medications.
Patients with certain heart conditions that are not well controlled.
Patients with liver disease or abnormal liver function tests.
Patients with a history of drug or alcohol abuse in the past year.
Patients who have participated in another clinical trial in the past 4 weeks.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Verified
Aarhus University Hospital
Aarhus, Denmark
Responsive
KBC Zagreb
Zagreb, Croatia
Responsive
North Estonia Medical Centre Foundation
Tallin, Estonia

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Upadacitinib is a medication being studied for its potential to help people with moderate to severe atopic dermatitis, which is a type of skin condition that causes red, itchy, and inflamed skin. This medication works by targeting specific pathways in the immune system that are involved in causing inflammation. By doing so, it aims to reduce the symptoms of atopic dermatitis, such as itching and skin rashes, and improve the overall condition of the skin. The goal of using upadacitinib in this trial is to see if it can effectively and safely help people who need more than just topical treatments for their skin condition.

Upadacitinib

What is already known about the treatment

Upadacitinib – Upadacitinib is administered orally in the form of tablets and is currently being studied in clinical trials for its effectiveness in treating moderate to severe atopic dermatitis, a skin condition characterized by inflammation and itching. It is a medication that is gaining attention in medical literature for its potential benefits in managing this condition. The main therapeutic indication for upadacitinib is to help reduce the symptoms of atopic dermatitis in adolescents and adults who require systemic treatment. At the molecular level, upadacitinib works by inhibiting certain enzymes known as Janus kinases (JAKs), which play a role in the inflammatory process. It is classified pharmacologically as a JAK inhibitor, which helps to decrease inflammation and improve skin condition.

Investigated diseases

Atopic Dermatitis – Atopic Dermatitis is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin. It often begins in childhood but can occur at any age. The disease progresses through periods of flare-ups, where symptoms worsen, and remissions, where symptoms improve or disappear. The skin may become thickened and cracked over time due to persistent scratching. It is commonly associated with other atopic conditions such as asthma and hay fever. The exact cause is unknown, but it involves a combination of genetic, environmental, and immune system factors.